• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Micell begins MiStent clinical trial in Japan

November 29, 2016 By Sarah Faulkner

Micell begins MiStent clinical trial in JapanMicell Technologies said today that it began its Dessolve J randomized, double-blind study comparing its MiStent SES sirolimus eluting absorbable polymer coronary stent to the Xience V everolimus eluting coronary stent in patients with coronary artery disease.

The Durham, N.C.-based company touts its device as a bare-metal stent coated in crystalline drug, sirolimus, and an absorbable polymer, with the goal of providing local drug delivery.

The study’s primary endpoint will compare target lesion failure in the 12-month clinical outcomes of patients in both arms. Enrollment will take place at 10 sites throughout Japan, the company reported.

“We are pleased to enroll the first patient in this important study,” principal investigator Dr. Shigeru Saito said in prepared remarks. “This study is a historic one for Japan. It will provide us with valuable insights into the potential benefits of MiStent’s unique pharmacokinetic profile, with a rapidly absorbing polymer and extended elution of crystalline sirolimus.”

MiStent has won CE mark approval in the European Union, supported by clinical data from Dessolve I and II. Micell also completed enrollment of 1,400 patients for Dessolve III in December last year. Dessolve J will provide Japan-specific data to support a pre-market application with Japan’s Pharmaceuticals and Medical Devices Agency, which the company will file after the study is complete.

“Cardiovascular disease poses a significant health risk in Japan and even with recent improvements in coronary artery disease treatment, additional advances in drug-eluting stents are still needed,” Micell chairman & CEO Arthur Benvenuto said. “Studies of MiStent to date have demonstrated a desirable lack of late lumen loss over 18 months, a characteristic that makes MiStent a clinically meaningful improvement that could provide clinicians and patients worldwide with enhanced treatment options.”

Earlier this month, Micell raised $25.8 million in a new round of equity and debt financing, according to an SEC filing.

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured Tagged With: Micell Technologies

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS